GLOBAL IMMERSION EXPERIENCE
JULY 27-30, 2020
The Alzheimer’s Association® is a worldwide voluntary health organization dedicated to Alzheimer’s care, support and research. Our mission is to lead the way to end Alzheimer’s and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.

Our vision is a world without Alzheimer’s and all other dementia.™
### TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome from Leadership</td>
<td>2</td>
</tr>
<tr>
<td>Virtual Global Immersion Experience Schedule</td>
<td>4</td>
</tr>
<tr>
<td>Leadership Profiles</td>
<td>8</td>
</tr>
<tr>
<td>Zenith Society</td>
<td>14</td>
</tr>
<tr>
<td>Alzheimer’s Association Board of Directors</td>
<td>15</td>
</tr>
</tbody>
</table>

### IF YOU NEED ASSISTANCE

To RSVP, or if you have questions, please contact:

**Alicia Dorman**  
312.639.7320  
[aadorman@alz.org](mailto:aadorman@alz.org)
Welcome to our first-ever virtual Alzheimer’s Association International Conference® (AAIC®). While we are disappointed we cannot gather in person this year, we are pleased that an unprecedented number of scientists, policymakers, students and philanthropists — such as yourself — are able to participate in this unparalleled annual sharing of information and inspiration.

This has been a year like no other in terms of challenges faced and progress achieved, including advancements in dementia science. For the first time in more than a decade, new data that show promise for treating cognitive and functional decline will be submitted to the U.S. FDA for review. Ongoing development of blood tests holds great promise for earlier detection of diseases that lead to dementia — widening the window of opportunity for intervention once treatments are approved for use.

We are getting closer to achieving the national goal of effectively treating and preventing Alzheimer’s and other dementia thanks to growth in philanthropic support for dementia research, government funding of dementia research and the number of scientists devoting their careers to dementia research.

Your support of our research and advocacy efforts is what started this momentum — and is what sustains it today. It is because of you that we can lead, seed and speed the most promising dementia science in the world. Thank you for your leadership and your partnership. Together, we will realize our vision of a world without Alzheimer’s and all other dementia.

Harry Johns  
President and CEO  
Alzheimer’s Association  
Alzheimer’s Impact Movement

Maria C. Carrillo, Ph.D.  
Chief Science Officer  
Alzheimer’s Association
Welcome to the AAIC 2020 Global Immersion Experience.
For those of you who are joining us for the first time, we regret we cannot greet you in person.

It is of course because of COVID-19 that we are convening via videoconference, and we join with the world community in grieving the countless lives lost thus far. The pandemic has thrown into high relief the importance of medical research, and it has been illuminating to see pharmaceutical companies, academic institutions, governments and philanthropists marshal their resources to vanquish this new coronavirus. Where there is a will, there is a way.

The pandemic has also magnified the urgency of our own cause. As you may have witnessed firsthand, people living with dementia and their caregivers have been disproportionately affected by COVID-19 and the physical distancing precautions taken to slow its spread. The most difficult challenge many people will ever face has gotten even harder. We are inspired by how quickly and thoroughly the Alzheimer’s Association transitioned to virtual operations to continue delivering on its mission without interruption.

No organization is doing more than the Association to end dementia, and we are proud to support its work as members of the Zenith Society. If you do not already belong to our leadership group, we encourage you to learn more about how you can help ensure a dementia-free future for generations to come.

Debbie and Clay Jones
Co-Chairs
Alzheimer’s Association Zenith Society
## GLOBAL IMMERSION EXPERIENCE 2020 SCHEDULE

### Monday, July 27, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 8 – 9 a.m. Pacific | **AAIC Plenary Session**  
Proteostasis Failure in Alzheimer’s Disease and Related Dementias — New Clues to Pathogenesis and Therapy  
• Ralph A. Nixon, M.D., Ph.D., New York University Langone Medical Center |
| 9 – 10 a.m. Mountain   |  
10 – 11 a.m. Central   |  
11 a.m. – 12 p.m. Eastern |
| 11 a.m. – 12:30 p.m. Pacific | **Zenith Society Business Meeting**  
— Members Only  
Welcome  
• Harry Johns, Alzheimer’s Association |
| 12 – 1:30 p.m. Mountain   |  
1 – 2:30 p.m. Central   |  
2 – 3:30 p.m. Eastern |
| 1 – 2 p.m. Pacific | **Zenith Society Impact Report**  
• Debbie and Clay Jones, Alzheimer’s Association Zenith Society |
| 2 – 3 p.m. Mountain   |  
3 – 4 p.m. Central   |  
4 – 5 p.m. Eastern |
| 2 – 3 p.m. Mountain   | **Zenith Society Member Study Findings**  
• Donna McCullough, Alzheimer’s Association |
| 3 – 4 p.m. Central   |  
4 – 5 p.m. Eastern |
| 1 – 2 p.m. Pacific | **Research Update**  
• Maria C. Carrillo, Ph.D., Alzheimer’s Association |
| 2 – 3 p.m. Mountain   |  
3 – 4 p.m. Central   |  
4 – 5 p.m. Eastern |
| 1 – 2 p.m. Pacific | **Zenith Fellows Updates**  
• Suzanne Craft, Ph.D., Wake Forest School of Medicine  
• Costantino Iadecola, M.D., Weill Cornell Medicine  
• Ron Petersen, M.D., Ph.D., Mayo Clinic |
| 2 – 3 p.m. Mountain   |  
3 – 4 p.m. Central   |  
4 – 5 p.m. Eastern |

The Alzheimer’s Association International Conference (AAIC) is the largest and most influential meeting dedicated to advancing dementia science. Each year, AAIC convenes the world’s leading basic science and clinical researchers, next-generation investigators, clinicians and the care research community to share research discoveries that will lead to methods of prevention and treatment and improvements in Alzheimer’s disease diagnosis and care.
Tuesday, July 28, 2020

**AAIC Plenary Session**
- **Imaging Biomarkers and Alzheimer’s Prevention**
  - Susan M. Landau, Ph.D., University of California, Berkeley
- **Blood Based Biomarkers**
  - Charlotte Teunissen, Ph.D., Amsterdam UMC

**ALZ Talk**
- **The State of the Alzheimer’s Association**
  - Harry Johns, Alzheimer’s Association

**Panel Discussion**
- **Inflammation: Advancements in Drug Development**
  Moderated by Bruce Lamb, Ph.D., Indiana University School of Medicine
  - CJ Barnum, Ph.D., INmune Bio, Inc.
  - Malú Tansey, Ph.D., University of Florida
  - Linda Van Eldik, Ph.D., University of Kentucky

Brain inflammation is a hallmark of Alzheimer’s disease. Recent research suggests that brain inflammation contributes directly to the build-up of amyloid “plaques” and other brain changes seen in Alzheimer’s. Research teams worldwide are investigating a number of ways to control neuroinflammation, including experimental and repurposed drugs and devices. Panelists will discuss promising candidates in the drug pipeline.
<table>
<thead>
<tr>
<th>Event Type</th>
<th>Time</th>
<th>Timezones</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| AAIC Plenary Session | 8 – 9 a.m. Pacific    | Pacific, Mountain, Central, Eastern | Mechanisms of Neurovascular Dysfunction and Interaction with Alzheimer’s Disease Pathology  
• Costantino Iadecola, M.D., Weill Cornell Medicine  
Early-Onset Alzheimer’s Disease  
• Nick Fox, M.D., University College London |
| ALZ Talk           | 11 a.m. – 12 p.m. Pacific | Pacific, Mountain, Central, Eastern | 2020 Public Policy Priorities and Strategies  
• Rob Egge, Alzheimer’s Association |
| Panel Discussion   | 1 – 2 p.m. Pacific     | Pacific, Mountain, Central, Eastern | Vascular Contributions to Dementia: Risk Factors and Prevention  
Moderated by Keith Fargo, Ph.D., Alzheimer’s Association  
Panelists:  
• Eliezer Masliah, M.D., National Institute on Aging  
• Sudha Seshadri, M.D., UT Health San Antonio  
• Rachel Whitmer, Ph.D., University of California, Davis  
• Donna Wilcock, Ph.D., University of Kentucky |

Several conditions known to increase the risk of cardiovascular disease also increase the risk of developing Alzheimer’s. Some autopsy studies suggest that “plaques” and “tangles” may be present in the brain without causing symptoms of cognitive decline unless the brain also shows evidence of vascular disease. Panelists will discuss common risk factors for vascular disease and dementia — such as high blood pressure, diabetes and high cholesterol — and research into ways to potentially prevent dementia by controlling them.
### Thursday, July 30, 2020

<table>
<thead>
<tr>
<th>Time</th>
<th>Pacific</th>
<th>Mountain</th>
<th>Central</th>
<th>Eastern</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 – 9 a.m.</td>
<td>AAIC Plenary Session</td>
<td>9 – 10 a.m.</td>
<td>10 – 11 a.m.</td>
<td>11 a.m. – 12 p.m.</td>
</tr>
<tr>
<td>11 a.m. – 12 p.m.</td>
<td>ALZ Talk</td>
<td>12 – 1 p.m.</td>
<td>1 – 2 p.m.</td>
<td>2 – 3 p.m.</td>
</tr>
<tr>
<td>1 – 2 p.m.</td>
<td>Panel Discussion</td>
<td>2 – 3 p.m.</td>
<td>3 – 4 p.m.</td>
<td>4 – 5 p.m.</td>
</tr>
<tr>
<td>11 a.m. – 12 p.m.</td>
<td>Alzheimer’s Association Response to COVID-19</td>
<td>12 – 1 p.m.</td>
<td>1 – 2 p.m.</td>
<td>2 – 3 p.m.</td>
</tr>
<tr>
<td>1 – 2 p.m.</td>
<td>Tau: Early Detection and Targets for Treatment</td>
<td>2 – 3 p.m.</td>
<td>3 – 4 p.m.</td>
<td>4 – 5 p.m.</td>
</tr>
</tbody>
</table>

#### AAIC Plenary Session
- **Global Guidelines for Dementia Risk Reduction**
  - Kaarin Anstey, Ph.D., UNSW-Sidney, Australia
- **Epidemiology of Dementia in Diverse Populations**
  - Lisa L. Barnes, Ph.D., Rush University Medical Center

#### ALZ Talk
- **Alzheimer’s Association Response to COVID-19**
  - Joanne Pike, Dr.P.H., Alzheimer’s Association

#### Panel Discussion
- **Tau: Early Detection and Targets for Treatment**
  - Moderated by Rebecca Edelmayer, Ph.D., Alzheimer’s Association
  - Panelists:
    - Karen Ashe, M.D., Ph.D., University of Minnesota
    - Lea Grinberg, M.D., Ph.D., University of California, San Francisco
    - Susan Landau, Ph.D., University of California, Berkeley
    - Henrik Zetterberg, M.D., Ph.D., Vanderbilt University

Toxic tau protein is associated with a number of neurodegenerative disorders, including Alzheimer’s disease, Parkinson’s disease, dementia with Lewy bodies and frontotemporal dementia. New research suggests that tau begins to degrade into “tangles” much sooner than previously realized, creating potential opportunities to intervene earlier. Panelists will discuss the development of new screening tools, drug targets, pharmacologic agents and other therapeutic strategies for tau-related diseases.
Harry Johns is the president and CEO of the Alzheimer’s Association, the global leader in Alzheimer’s and dementia information, advocacy, research and support.

The Alzheimer’s Association has created and driven the public discussion about Alzheimer’s in America, raising the cause to unprecedented levels of recognition and support. Through its nationwide community programs of care and support, as well as a 24/365 helpline, and around the world through alz.org, the Association reaches more than 40 million people annually. The advocacy of the Association has achieved significant public policy gains, including increases in annual federal research funding to $2.8 billion, including $350, $400, $414, $425 and $350 million increases in the past five years, in addition to significant legislative and regulatory advances in care and support. The Association’s global leadership in dementia research also includes direct commitments of $208 million in 31 countries today, participation in nearly every major scientific advance and annually convening the world’s largest gathering of such researchers. InCites Clarivate ranks the Alzheimer’s Association first among all nonprofits worldwide for its dementia research impact and third among all organizations including governments. And, since the evaluation began, the Alzheimer’s Association has been recognized as one of The Nonprofit Times Best Nonprofits to Work For. Since 2009, the Association has placed among the top three large nonprofits.

Harry is currently serving a two-year term as the Chair of the World Dementia Council, where he has served since 2014, appointed by the UK government on behalf of the G8. He also serves as president and CEO of the Alzheimer’s Impact Movement (AIM), a separately incorporated advocacy affiliate of the Alzheimer’s Association. From 2011 to 2017 he served as a member of the Advisory Council on Alzheimer’s Research, Care, and Services, appointed by the U.S. Secretary of Health and Human Services. In 2018, he was named to The Nonprofit Times’ Power & Influence Top 50, a list that recognizes nonprofit executives for their innovation and leadership.

Prior to joining the Alzheimer’s Association, Harry was on the executive team of the American Cancer Society. He is a graduate of Eckerd College and the Northwestern University Kellogg School of Business.
Joanne Pike, Dr.P.H., is the chief strategy officer of the Alzheimer’s Association. In this role she oversees the Association’s strategic plan to advance risk reduction, care and support, research, advocacy, diversity and inclusion, concern and awareness, and fundraising.

During her 25 years in progressive leadership in social support and public health, Dr. Pike has developed and executed successful health-focused initiatives while implementing revenue strategies to support those outcomes.

At the Alzheimer’s Association, she oversees care and support services offered across the organization to those affected by the disease; outreach aimed at creating partnerships with health systems, physicians and other health care professionals; long-term care initiatives focused on person-centered care delivery models; and growth strategies for reaching more individuals through quality improvement, education, and supportive programs and services.

Dr. Pike is responsible for guiding the implementation of the Association’s Dementia Care Practice Recommendations, which establish a new foundation in quality care for individuals living with Alzheimer’s and other dementias. The product line — which includes essentiALZ® certification and curriculum review — is designed to train professional care providers to deliver high-quality, person-centered care to people living with Alzheimer’s and other dementias.

Throughout her career, she has successfully leveraged public policy to advance such public health outcomes with a particular emphasis on outreach to diverse communities.

Prior to joining the Association, Dr. Pike spent 13 years in leadership positions at the American Cancer Society and three years as executive director of the Preventive Health Partnership, a collaboration between the American Cancer Society, the American Diabetes Association and the American Heart Association aimed at preventing cancer, diabetes, heart disease and stroke. Dr. Pike’s educational background includes a doctorate in public health leadership, focused on health policy and management, from the University of North Carolina at Chapel Hill.
Donna McCullough is the chief field and development officer of the Alzheimer’s Association, overseeing the strategy for the Association’s network of more than 70 chapters as well as revenue initiatives to advance the organization as the leading voluntary health organization in Alzheimer’s care, support and research.

McCullough has significant large nonprofit experience in creating and developing strategy, planning and execution in key areas of fundraising, constituent service and public policy. She currently provides strategic leadership to all aspects of individual and corporate philanthropic support for the Association, including mass market events, large-scale relationship events, direct marketing, major and strategic gifts, planned giving, corporate partnerships and foundations.

Under McCullough’s leadership, Walk to End Alzheimer’s® is the only large charity walk in the United States that has grown its annual revenue each year since 2006, ranking as the third-largest peer-to-peer fundraising event in the country. The Longest Day® brings thousands of participants from across the world together to take part in a fundraising activity of their choice, and is among the nation’s fastest growing do-it-yourself events. Due to the success of these two signature fundraising events, the Association was named Fundraising Organization of the Year in 2019 by the Peer-to-Peer Professional Forum. Ride to End ALZ™, a new cycling event, will launch in 2020.

The Association’s relationship events, such as Part the Cloud, the Imagine Fall Benefit, the Rita Hayworth Gala, Inspire Napa Valley Wine Weekend and Dance Party to End ALZ, receive national publicity for their work raising funds and awareness for the cause.

McCullough successfully leads Step Up the Pace, a strategic giving initiative focused on accelerating Alzheimer’s research. With the generous support of major individual, corporate and foundation donors, the Association has raised an unprecedented $173 million since 2014.

To address mutual concerns around Alzheimer’s disease, McCullough also oversees significant nationwide, regional and local corporate partnerships with companies such as Edward Jones, TJX, CVS and Bankers Life.

McCullough earned her bachelor’s degree in business management from the University of West Florida and has advanced leadership training from the Kellogg School of Management, Harvard University and Mutual of America.
As chief science officer, Maria C. Carrillo, Ph.D., sets the strategic vision for the Alzheimer’s Association global research program. Under her leadership, the Association is the world’s largest nonprofit funder of Alzheimer’s research and an internationally recognized pioneer in convening the dementia science community to accelerate the field. As a noted public speaker, Dr. Carrillo plays an instrumental role in the Association’s efforts to lobby both the public and private sectors for increased funding for the disease.

Dr. Carrillo oversees the implementation of the Association’s growing portfolio of research initiatives, including the Alzheimer’s Association International Conference (AAIC), the world’s largest and most influential dementia science meeting, and the Research Roundtable, which enables international scientific, industry and government leaders to work together to overcome shared obstacles in Alzheimer’s science and drug development. In addition, Carrillo manages the World Wide Alzheimer’s Disease Neuroimaging Initiative (WW-ADNI), a multi-country research effort aimed at accelerating the early detection of Alzheimer’s.

Under Dr. Carrillo’s direction, the Association’s leadership in Alzheimer’s research continues to thrive through its International Research Grant Program, which is currently investing $208 million in more than 590 active best-of-field projects in 31 countries. In addition, the Association has expanded its role in advancing dementia science by becoming directly involved in research. Dr. Carrillo is a co-primary investigator for the Association-funded and led U.S. POINTER study, a lifestyle intervention trial to prevent cognitive decline and dementia.

Dr. Carrillo has published extensively on early diagnosis and biomarker standardization efforts, as well as on the global challenges to progress for research in Alzheimer’s and dementia. She is a co-author of the “Appropriate Use Criteria for Amyloid Imaging,” published by the Society of Nuclear Medicine and Molecular Imaging and the Alzheimer’s Association.

As an internationally respected Alzheimer’s expert, Dr. Carrillo has been featured in numerous media outlets, including The New York Times, The Wall Street Journal, Time magazine and “NBC Nightly News with Lester Holt.” Dr. Carrillo sits on the governing board of the Global Brain Health Institute and is on the advisory committee for the World Health Organization Dementia Setting Priorities & Portfolio Analysis. She also is a member of the American Heart Association’s research committee.

Dr. Carrillo earned her Ph.D. from Northwestern University’s Institute for Neuroscience and completed a postdoctoral fellowship focused on Alzheimer’s brain imaging and risk factors at Rush University Medical Center in Chicago.
Robert Egge is the chief public policy officer of the Alzheimer’s Association and the executive director of the Alzheimer’s Impact Movement (AIM), a separately incorporated advocacy affiliate of the Association. In these roles, Egge oversees government affairs, policy development and grassroots advocacy teams working to secure policies to improve the lives of all those affected by dementia.

Since joining the organization in 2009, Egge has led the Association in achieving several major milestones in Alzheimer’s policy, including the passage of the National Alzheimer’s Project Act (NAPA), which mandated the creation of the first national plan to fight Alzheimer’s. He managed the Association’s efforts to enact the bipartisan BOLD Infrastructure for Alzheimer’s Act, legislation that is critical to addressing Alzheimer’s as a public health issue. Under Egge’s guidance, the Association has successfully lobbied Congress for significant increases in funding for Alzheimer’s disease research, more than quintupling funding levels since the passage of NAPA.

Egge also drove the Association’s support for a 2016 decision by the Centers for Medicare & Medicaid Services to ensure people with Alzheimer’s have access to care planning with a medical professional through Medicare for the first time in history. In addition, Egge has overseen efforts to increase the number of state Alzheimer’s plans so the disease can be more effectively addressed on the local level. Today, 46 states plus the District of Columbia and Puerto Rico have plans in place.

Egge was appointed to the U.S. Department of Health and Human Services’ Advisory Council on Alzheimer’s Research, Care, and Services in 2017. This advisory council, created by the National Alzheimer’s Project Act, provides guidance to both the secretary and the United States Congress on matters of Alzheimer’s policy.

Prior to joining the Alzheimer’s Association, Egge served as executive director of the Alzheimer’s Study Group, a blue-ribbon task force co-chaired by former House Speaker Newt Gingrich and former Nebraska Senator Bob Kerrey. Egge led the group in a review of the challenges posed by the mounting Alzheimer’s crisis, and managed the development of the group’s national assessment, strategy and specific policy proposals.

Egge’s articles and editorials have appeared in a variety of publications including The New York Times, the Financial Times and Health Affairs. He is often invited to testify before Congress on Alzheimer’s issues, and frequently speaks on Alzheimer’s policy through television, radio and print interviews.
Debbie Jones has been a highly motivated and active philanthropist and community volunteer for the past 30 years, serving on the boards of directors of the Alzheimer’s Association and its East Central Iowa Chapter, the Alzheimer’s Impact Movement, United Way, Meals on Wheels, Goodwill and Orchestra Iowa. Her mother’s 10-year battle with Alzheimer’s disease sparked Mrs. Jones’s steadfast resolve to help advance treatments through research and to enhance quality care and support through education.

Mrs. Jones has performed numerous public speaking roles for the Alzheimer’s Association including at its annual Alzheimer’s Association International Conference; Advocacy Forum in Washington, DC; and Leadership Summit. She and her husband, Clay, became the co-chairs of the Alzheimer’s Association Zenith Society in 2016. They have two daughters and five grandchildren, and they now reside in Naples, Florida.

Clay Jones retired from Rockwell Collins Inc. in July 2013 as its chief executive officer and in July 2014 as its chairman. Mr. Jones joined Rockwell International in 1979 and assumed progressive leadership roles that in 1995 took him to Cedar Rapids, Iowa, as vice president and general manager for Collins Air Transport Division. In 1998 Mr. Jones was appointed president of Rockwell Collins and corporate officer and senior vice president of Rockwell International.

Mr. Jones is a member of the boards of directors of John Deere and Motorola Solutions and previously served on the boards of Rockwell Collins, Cardinal Health, and Unisys. During his career, he served as chairman of the Aerospace Industries Association and General Aviation Manufacturers Association and on the board of the Smithsonian National Air and Space Museum. He is a former member of The Business Council, The Business Roundtable, and the President’s National Security Telecommunications Advisory Committee. Clay serves as co-chair of the Alzheimer’s Association Zenith Society with his wife, Debbie.

Mr. Jones graduated from the University of Tennessee in 1971 with a bachelor’s degree in political science and received his MBA from George Washington University in 1986. He served in the U.S. Air Force as a fighter pilot from 1971 to 1979.
Established in 1990, the Alzheimer’s Association Zenith Society sets the bar for philanthropic leadership, engagement and impact. Its 89 members have collectively invested more than $165 million to advance Alzheimer’s research, advocacy, awareness, and care and support.

**Philanthropic leadership.** The Zenith Society’s unparalleled commitment inspires others to join the Alzheimer’s movement. In addition to making generous personal investments to launch and sustain key initiatives, members organize fundraising events, fund matching-gift challenges, and spearhead engagement opportunities to attract new supporters to the cause.

**Deep engagement.** Zenith Society members partner with the Alzheimer’s Association as ambassadors, advocates, and volunteers, contributing invaluable experience and knowledge. Members attend major research and policy events, meet with Association leadership, and work directly with medical and scientific experts to identify and support high-potential Alzheimer’s research projects.

**Transformational impact.** The Zenith Society is helping change the course of Alzheimer’s disease through visionary investments. The Zenith Fellows Awards program has provided more than $40 million to 138 leading Alzheimer’s researchers whose pivotal discoveries have opened new possibilities for early detection, diagnosis, treatment and prevention. Zenith Society members also help launch special research Initiatives. These have included the Alzheimer’s Association Global Consortium for Biomarker Standardization, the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), the Global Alzheimer’s Association Interactive Network (GAAIN) and the U.S. Study to Protect Brain Health through Lifestyle Intervention to Reduce Risk (U.S. POINTER).
# ALZHEIMER’S ASSOCIATION BOARD OF DIRECTORS

<table>
<thead>
<tr>
<th><strong>Chair</strong></th>
<th><strong>Directors</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>David Goltermann</td>
<td>Helen Brooks</td>
</tr>
<tr>
<td></td>
<td>Andrew Dahlkemper</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Chair Elect</strong></th>
<th><strong>Directors</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Richardson</td>
<td>Thomas Doyle, Ed.D.</td>
</tr>
<tr>
<td></td>
<td>Geoff Heredia</td>
</tr>
<tr>
<td></td>
<td>David Hunter</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Secretary</strong></th>
<th><strong>Directors</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>James Grossmann</td>
<td>Minoo Javanmardian, Ph.D.</td>
</tr>
<tr>
<td></td>
<td>George Johnson</td>
</tr>
<tr>
<td></td>
<td>Karyne Jones</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Treasurer</strong></th>
<th><strong>Directors</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Julia Wallace</td>
<td>Eileen Kamerick</td>
</tr>
<tr>
<td></td>
<td>Ryan Mundy</td>
</tr>
<tr>
<td></td>
<td>Steve Osgood</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Executive Committee</strong></th>
<th><strong>Directors</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bruce Baude</td>
<td>Debra Pierson, PMP</td>
</tr>
<tr>
<td>Anna Catalano</td>
<td>Jay Reinstein</td>
</tr>
<tr>
<td>Cynthia Lemere, Ph.D.</td>
<td>William Thomas</td>
</tr>
<tr>
<td>Sarah Lorance</td>
<td>Carolyn Tieger</td>
</tr>
<tr>
<td>Cecile Perich</td>
<td>Alex Tsao, Ph.D.</td>
</tr>
<tr>
<td>Karen Stevenson</td>
<td>Derek van Amerongen, M.D</td>
</tr>
</tbody>
</table>

George Walz
To RSVP, or for questions, please contact:

Alicia Dorman
312.639.7320
aadorman@alz.org